CSF phospho-tau is independent of age, cognitive status and gender of neurological patients (Q39908117)

15 September 2017

title

CSF phospho-tau is independent of age, cognitive status and gender of neurological patients (English)

1 reference

15 September 2017

Armin Scheurich

1

1 reference

15 September 2017

Peter P Urban

series ordinal

2

1 reference

15 September 2017

Nassrin Koch-Khoury

series ordinal

3

1 reference

15 September 2017

Andreas Fellgiebel

series ordinal

4

1 reference

15 September 2017

publication date

17 November 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

257

1 reference

15 September 2017

issue

4

1 reference

15 September 2017

page(s)

609-614

1 reference

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease

15 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-009-5382-1

Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

21 January 2018

1 reference

12 December 2020

Variation with age in the volumes of grey and white matter in the cerebral hemispheres of man: measurements with an image analyser

1 reference

12 December 2020

A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy

1 reference

12 December 2020

Cerebrospinal fluid tau levels increase with age in healthy individuals

1 reference

12 December 2020

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

1 reference

12 December 2020

Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure

1 reference

12 December 2020

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

1 reference

12 December 2020

CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type

1 reference

12 December 2020

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.

1 reference

12 December 2020

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

1 reference

12 December 2020

Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231.

1 reference

12 December 2020

Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury

1 reference

12 December 2020

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

1 reference

12 December 2020

Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.

1 reference

12 December 2020

Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity

1 reference

12 December 2020

ICD-10 checklists--a tool for clinicians' use of the ICD-10 classification of mental and behavioral disorders.

1 reference

12 December 2020

The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

1 reference

12 December 2020

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

1 reference

12 December 2020

Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease

1 reference

12 December 2020

Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

1 reference

12 December 2020

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

1 reference

12 December 2020

Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins

1 reference

12 December 2020

Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases

1 reference

12 December 2020

Normal neuroanatomical variation due to age: the major lobes and a parcellation of the temporal region

1 reference

12 December 2020

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

1 reference

12 December 2020

Increased CSF tau protein in corticobasal degeneration

1 reference

12 December 2020

Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.

1 reference

12 December 2020

Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis

1 reference

12 December 2020

Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein

1 reference

12 December 2020

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

1 reference

12 December 2020

10.1007/S00415-009-5382-1

Identifiers

DOI

1 reference

15 September 2017

1 reference